卫光生物: 第四届董事会第一次会议决议公告

Group 1 - The company held its fourth board meeting on July 17, 2025, with all nine directors present, and the meeting complied with relevant laws and regulations [1][2] - Zhang Zhan was elected as the chairman of the fourth board of directors, serving from the date of approval until the term ends [2][3] - The board approved the establishment of various committees, including the Audit Committee, Strategy Committee, Nomination Committee, and Compensation and Assessment Committee, with specific members appointed [2][3] Group 2 - The board approved the appointment of senior management, including Guo Caiping as General Manager and Chen Guanqun as Financial Officer, with all appointments effective immediately [3][4] - The compensation plan for the board members was discussed, with specific salary standards set for different roles, including independent directors [4][5] Group 3 - The company plans to issue A-shares to specific investors, with a total fundraising target of up to 1.5 billion yuan, subject to shareholder approval [5][9] - The issuance will be conducted through a private placement, with shares priced at no less than 80% of the average trading price over the previous 20 trading days [6][7] - The maximum number of shares to be issued will not exceed 20% of the total share capital before the issuance [8][9] Group 4 - The funds raised will be used for projects closely related to the company's main business, with a total investment of approximately 2.607 billion yuan planned for various projects [9][12] - The company will ensure that any shortfall in the raised funds will be covered by self-raised funds, and the projects will be prioritized based on urgency [10][12] Group 5 - The company will implement a shareholder return plan for the next three years (2025-2027), focusing on enhancing transparency and protecting shareholder rights [15][16] - The company plans to invest in the Weiguang Biological Intelligent Industry Base project, with a total investment of about 2.3 billion yuan [16][17] Group 6 - The board approved adjustments to the estimated annual related party transaction limits based on actual business needs [17] - The company will hold its second extraordinary general meeting of 2025 on August 7, 2025, to discuss various matters [17]